PRESS RELEASE published on 05/08/2024 at 12:30, 4 months 11 days ago A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox NanoViricides reports NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox via inhalation and skin transmission. Study highlights efficacy in lethal animal models, supporting clinical development potential NanoViricides NV-387 Clinical Development Orthopoxvirus Antiviral
BRIEF published on 05/06/2024 at 12:35, 4 months 13 days ago NanoViricides rapporte des résultats prometteurs pour le NV-387 dans le traitement de la grippe A NanoViricides NV-387 Grippe A Médicaments Antiviraux Grippe Aviaire H5N1
BRIEF published on 05/06/2024 at 12:35, 4 months 13 days ago NanoViricides Reports Promising Results for NV-387 in Treating Influenza A NanoViricides NV-387 Antiviral Drugs Influenza A H5N1 Bird Flu
PRESS RELEASE published on 05/06/2024 at 12:30, 4 months 13 days ago A Novel Broad-Spectrum Antiviral with Activity Against Influenza A NanoViricides reports strong anti-influenza activity of NV-387, suggesting effectiveness against H5N1 bird flu virus. Results show superior performance to approved drugs. Further studies needed for confirmation NanoViricides NV-387 Anti-influenza H5N1 Drug
BRIEF published on 04/30/2024 at 12:35, 4 months 19 days ago NanoViricides Announces Successful Completion of Phase I Clinical Trial for NV-387 NanoViricides NV-387 Phase I Clinical Trial Antiviral Treatment RSV Infection
BRIEF published on 04/30/2024 at 12:35, 4 months 19 days ago NanoViricides annonce la réussite de l'essai clinique de phase I pour le NV-387 NanoViricides NV-387 Essai Clinique De Phase I Traitement Antiviral Infection Par Le VRS
PRESS RELEASE published on 04/30/2024 at 12:30, 4 months 19 days ago NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination NanoViricides NV-387 Phase I Clinical Trial Phase II Discussion Antiviral Drug
PRESS RELEASE published on 02/15/2024 at 12:30, 7 months 4 days ago NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon NanoViricides, Inc. files Quarterly Report on Form 10-Q with SEC, reports financial status and cash balance of $5.31 Million. Company makes strategic moves to improve liquidity and prepares for Phase II clinical trials Quarterly Report Clinical Trials Form 10-Q NanoViricides Inc. Financial Status
PRESS RELEASE published on 02/01/2024 at 12:20, 7 months 18 days ago Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics NanoViricides, Inc. reports on the strong safety and tolerability of NV-CoV-2 oral drug products, showcasing their potential for long-term success and broad-spectrum antiviral capabilities, including against RSV and Smallpox-like viruses NV-387 NanoViricides Inc Antiviral Drugs Nanoviricides Platform COVID Therapeutics
PRESS RELEASE published on 01/29/2024 at 12:30, 7 months 21 days ago Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
Published on 09/20/2024 at 02:00, 2 hours 28 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 5 hours 13 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 5 hours 28 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 5 hours 28 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 7 hours 18 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 9 hours 43 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 10 hours 24 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 10 hours 35 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 10 hours 35 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 10 hours 43 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 10 hours 43 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 10 hours 43 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)